• About Us
    • About Us
    • Corporate Strategy
    • Our Vision and Values
    • Research & Development
    • Operations
    • Business Development
    • Awards and Grants
  • Announcements
  • Our Team
    • Management Team
    • Scientific Team
    • Scientific Advisory Board
  • Portfolio
    • Our Portfolio
    • Lupuzor™ & Lupus
    • Autoimmunity
    • Anti-infectives
  • Investors
    • Investor Relations
    • AIM Rule 26 Information
    • Regulatory News
    • Market Commentary
    • Share Price
    • Analyst Research
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Interviews
    • Professional Advisers
    • Email Alerts
  • Media
    • Events and Conferences
    • Media Room
    • Interviews
    • Scientific Publications
  • Contact Us
November 21, 2020

Stock Watch – ImmuPharma (Daily Mail | 21 November 2020)

Read More
November 20, 2020

ImmuPharma’s US partner to meet with FDA in December regarding Lupuzor trial

Read More
November 20, 2020

ImmuPharma says US partner makes regulatory and operational progress ahead of phase III trial of lupus drug

Read More
September 02, 2020

ImmuPharma raises £6.5m to invest in pipeline of up-and-coming drug

Read More
July 27, 2020

ImmuPharma notes new FDA submission for Lupuzor™

Read More
July 27, 2020

Rachel Brazil, Chemisty World, talks to the people trying to create foldamers including Dimitri Dimitriou, chief executive, Immupharma PLC

Read More
July 27, 2020

ImmuPharma partner looks to streamline phase III approval process for lupus drug

Read More
June 11, 2020

ImmuPharma attracts first funding from US healthcare specialists – 11 June 2020

Read More
May 14, 2020

ImmuPharma surges as US study shows potential for Lupuzor to reduce coronavirus symptoms – 14 May 2020

Read More
February 06, 2020

ImmuPharma expects second phase III lupus trial to get underway as soon as possible this year

Read More
December 19, 2019

ImmuPharma commences trading on Euronext Growth Brussels 19 December 2019

Read More
December 13, 2019

ImmuPharma PLC (LON:IMM) announced that its shares will be dual-listed on Euronext Growth Brussels with effect from 19 December 2019, following approval by the European exchange, a move which will bring the company “additional visibility among European investor

Read More
  • 1
  • 2
  • 3
  • 4
Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2021 | All rights reserved